JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2024, 79(4):213-219 | DOI: 10.55095/CSPediatrie2024/008

Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)

Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin
Klinika detí a dorastu, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Univerzitná nemocnica Martin, Slovensko

Patients with inflammatory bowel diseases show significant differences in phenotypic manifestation as well as responses to treatment. Significant interindividual variability in therapeutic response has led in recent years to research initiatives aimed at identifying genetic markers capable of optimizing the treatment. For example, investigation of predictive markers of thiopurine-induced myelosupp

ression has been implemented into clinical practice. On the other hand, markers related to new treatment options such as biological treatment are not yet used in common clinical practice.

The article offers an overview of advances in the field of IBD pharmacogenetics, summarizes known pharmacogenetic markers as well as the candidate genes and their prospective use in the personalization of IBD treatment.

Keywords: inflammatory bowel disease, children, pharmacogenetics, personalized treatment

Received: October 5, 2023; Revised: December 30, 2023; Accepted: January 2, 2024; Published: August 1, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kosorínová D, Suchá P, Havlíčeková Z, Pršo M, Dvoran P, Bánovčin P. Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD). Ces-slov Pediat. 2024;79(4):213-219. doi: 10.55095/CSPediatrie2024/008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 2022; 162: 1147-1159. Go to original source... Go to PubMed...
    2. Peyerin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: Impact of mucosal healing on the course of the inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-83. Go to original source... Go to PubMed...
    3. Pariente B, Hu S, et al. Treatments for Crohn's disease-associated bowel damage: a systematic review. Clin Gastroenterol Hepatol 2019; 17: 847-856. Go to original source... Go to PubMed...
    4. Van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2020. doi: 10.1093/ecco-jcc/jjaa161 Go to original source... Go to PubMed...
    5. Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016; 14(3): 348-354. Go to original source... Go to PubMed...
    6. Ruemmele FM, Veres G, Kolho K, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014; 8(10): 1179-1207. Go to original source... Go to PubMed...
    7. Chang J, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease. A review. Precision and future medicine 2021; 5(4): 151-163. Go to original source...
    8. Turner D, Levine A, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. JPGN 2018; 67: 257-291. Go to original source... Go to PubMed...
    9. Hausmann M, Paul G, et al. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol 2008; 46: 259-65. Go to original source... Go to PubMed...
    10. Ricart E, Taylor WR, et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 1763-8. Go to original source... Go to PubMed...
    11. Wang Y, Parker C, Faegan B, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 4(4): 567-589. Go to original source... Go to PubMed...
    12. Bressler B, Marshall J, Bernstein Ch, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015; 148 (5): 1035-58. Go to original source... Go to PubMed...
    13. Heap GA, So K, Edney N, et al. Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohns Colitis 2016; 10(2): 149-158. Go to original source... Go to PubMed...
    14. Suzuki K, Kakuta Y, Naito T, et al. Genetic background of mesalamine-induced fever and diarrhea in Japanese patients with inflammatory bowel disease. Inflamm Bowel Dis 2022; 28(1): 21-31. Go to original source... Go to PubMed...
    15. Hayes MP, Roman DL. Regulator of G protein signaling 17 as a negative modulator of GPCR signaling in multiple human cancers. AAPS J 2016; 18: 550-9. Go to original source... Go to PubMed...
    16. Chande N, Patton P, Tsoulis D, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2015. CD000067 Go to original source...
    17. Chaparro M, Ordás I, Cabré E, et. al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19(7): 1404-10. Go to original source... Go to PubMed...
    18. Chang J, Cheon J. Thiopurine therapy in patients with inflammatory bowel disease: a focus on metabolism and pharmacogenetics. Dig Dis Sci 2019; 64: 2395-403. Go to original source... Go to PubMed...
    19. Qiu Y, Mao R, Zhang S, et al. Safety profile of thiopurines in Crohn disease: analysis of 893 patient-years follow-up in a Southern China cohort. Medicine (Baltimore) 2015; 94: e1513. Go to original source... Go to PubMed...
    20. Coelho T, Andreoletti G, Ashton J, et al. Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. Sci Rep 2016; 34658. Go to original source... Go to PubMed...
    21. Timmer A, Patton P, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016: CD000478. Go to original source...
    22. Paľuvová K, Škereňová M, Havlíčeková Z, et al. Farmakogenetika "nepriateľ" tiopurînových liečiv - kazuistiky. Z laboratória do klinickej praxe 1 2018; 155-159.
    23. Ooi C, Banerjee I, Chuah S, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019; 17: 285-310. Go to original source... Go to PubMed...
    24. Effenberger M, Reider S, Waschina S, et al. Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients. J Crohns Colitis 2021; 15(1): 88-98. Go to original source... Go to PubMed...
    25. Yang C, Singh P, Le M, et al. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41: 1079-1093. Go to original source... Go to PubMed...
    26. Matsuoka K. NUDT15 gene variants and thiopurine induced leukopenia in patients with inflammatory bowel disease. Intest Res 2020; 18: 275-81. Go to original source... Go to PubMed...
    27. Kim H, Cheon J, Jung E, et al. A coding variant in FTO confers susceptibility to thiopu- rine- induced leukopenia in East Asian patients with IBD. Gut 2017; 66: 1926-35. Go to original source... Go to PubMed...
    28. Van den Bosch B, Coenen M. Pharmacogenetics of inflammatory bowel disease, Future medicine 2020; 10: 2020-2095.
    29. Wilson A, Jansen L, Rose R, et al. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2018; 47: 615-20. Go to original source... Go to PubMed...
    30. Bangma A, Voskuil M, Venema W, et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther 2020; 51 (11): 1105-1115. Go to original source... Go to PubMed...
    31. Debashish M, Shefali K, Aman S, et al. Alopecia as the first manifestation of azathioprine myelosuppression in a genetically predisposed patient. Indian journal of rheumatology 2019; 14(1): 61-64. Go to original source...
    32. Gabryel M, Skrzypcak-Zielinska M, Kuchraski M, et al. The impact of genetic factors on response to glucocorticoids therapy in IBD. Scand J Gastroenterol 2016; 51: 654-665. Go to original source... Go to PubMed...
    33. Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res 2019. 17: 36-44. Go to original source... Go to PubMed...
    34. Sood A, Singh A, Sudhakar R, et al. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020; 18: 184-91. Go to original source... Go to PubMed...
    35. Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, et. al. Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease? Intest Res 2021; 19: 461-7. Go to original source... Go to PubMed...
    36. Singh A, Mahajan R, Kedia S, et al. Use of thiopurines in inflammatory bowel dissase: an update. Intest Res 2021; 33845546.
    37. Sazonovs A, Kennedy N, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology 2020; 158: 189-199. Go to original source... Go to PubMed...
    38. Lauro R, Mannino F, Irrera N, et al. Pharmacogenetics of biological agents used in inflammatory bowel disease: A systemic review. Biomedicines 2021; 9: 1748-1765. Go to original source... Go to PubMed...
    39. Netz U, Carter J, Eichenberger M, et al. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. World J Gastroenterol 2017; 23: 4958-4967. Go to original source... Go to PubMed...
    40. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-824. Go to original source...
    41. Chen W, Xu H, Wang X, et al. The tumor necrosis factor receptor superfamily member 1b polymorphisms predict response to anti-tnf therapy in patients with autoimmune disease: A meta-analysis. Int Immunopharmacol 2015; 28: 146-153. Go to original source... Go to PubMed...
    42. Wang Y, Parker C, Feagan B, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 4(4): 567-589. Go to original source... Go to PubMed...
    43. Mascheretti S, Hampe J, Croucher J, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15(NOD2) gene: An analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-515. Go to original source... Go to PubMed...
    44. Bank S, Julsgaard M, Abed O, et al. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019; 49: 890-903. Go to original source... Go to PubMed...
    45. Prieto-Pérez R, Almoguera B, Cabaleiro T, et al. Association between genetic polymorphisms and response to anti-TNFs in patients with inflammatory bowel disease. Int J Mol Sci 2016; 17: 225. Go to original source... Go to PubMed...
    46. Fujino S, Bamba S, Ogawa A, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2013; 52: 65-70. Go to original source... Go to PubMed...
    47. Hlavatý T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2015; 22: 613-626. Go to original source... Go to PubMed...
    48. Yamamoto-Furusho JK. Pharmacogenetics in inflammatory bowel disease: understatnding treatment response and personalizing therapeutic strategies. Pharmacogenomics and Pers Med 2017; 10: 197-204. Go to original source... Go to PubMed...
    49. Dubinsky M, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNF alpha therapeutic responsiveness in peditric inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1357-1366. Go to original source... Go to PubMed...
    50. Jung E, Choi K, et al. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019; 34: 1727-35. Go to original source... Go to PubMed...
    51. Erlandsson MC, Forslind K, et al. Metastatin S100A4 is increased in proportion to radiographic damage in patients with RA. Rheumatology (Oxford) 2012; 51: 932-40. Go to original source... Go to PubMed...
    52. Sandborn W, Feagan BG, et al. Safety of ustekinumab in inflammatory bowel disease: pooled safety analaysis of results from phase 2/3 studies. Inflamm Bowel Dis 2021; 27 (7): 95-1007. Go to original source... Go to PubMed...
    53. Hoffmann P, Lamerz D, et al. Gene polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in patients with Crohn's disease: on the way to personalized medicine? Genes (Basel) 2021; 12(6): 866. Go to original source... Go to PubMed...
    54. Lukáš M, et al. Idiopatické střevní záněty, nové trendy a mezioborové souvislosti, Grada 2020.
    55. Jung E, Choi K, Kim S, et al. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019; 34: 1727-35. Go to original source... Go to PubMed...
    56. Bangma A, Voskuil M, Venema W, et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther 2020; 51 (11): 1105-1115. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content